Drug Search Results
More Filters [+]

LX-1606

Alternative Names: lx-1606, lx1606, lx 1606
Latest Update: 2024-02-19
Latest Update Note: PubMed Publication

Product Description

Lexicon was developing lx-1606, an oral TPH Inhibitor for Carcinoid Syndrome. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT01104415)

Mechanisms of Action: TPH Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Lexicon
Company Location: THE WOODLANDS TX 77381
Company CEO: Lonnel Coats
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for LX-1606

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Carcinoid Tumor|Malignant Carcinoid Syndrome|Serotonin Syndrome|Other

Phase 2: Carcinoid Tumor|Serotonin Syndrome|Malignant Carcinoid Syndrome|Neuroendocrine Tumors|Colitis, Ulcerative

Phase 1: Malignant Carcinoid Syndrome|Serotonin Syndrome

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

NCI-2018-00294

P2

Recruiting

Neuroendocrine Tumors|Serotonin Syndrome|Malignant Carcinoid Syndrome|Carcinoid Tumor

2023-10-01

TELEPATH

P3

Completed

Serotonin Syndrome|Malignant Carcinoid Syndrome|Carcinoid Tumor

2018-09-12

62%

TELEPATH (Telotristat Etiprate – Expanded Treatment for Patients with Carcinoid Syndrome Symptoms)

P3

Completed

Unknown

2018-09-12

TELECAST

P3

Completed

Serotonin Syndrome|Carcinoid Tumor|Malignant Carcinoid Syndrome

2016-03-29

Recent News Events